CAS: 300-39-0; (S)-2-Amino-3-(4-Hydroxy-3,5-Diiodophenyl)Propanoic Acid

相似化合物

103213-31-6 16711-71-0 66-02-4

上下游产品

CAS号60-18-4 L-酪氨酸 | CAS号70-78-0 3-碘-L-酪氨酸 | CAS号7664-41-7 氨 | CAS号7553-56-2 碘 | CAS号51-48-9 左旋甲状腺素 | CAS号17194-82-0 对羟基苯乙酰胺 | CAS号60-18-4 L-酪氨酸 | CAS号21959-36-4 N-乙酰基-3,5-二碘-L-酪氨酸乙酯 | CAS号62129-53-7 N-叔丁氧羰基-3,5-二碘-L-酪氨酸 | CAS号76318-50-8 3,5-二碘-L-酪氨酸甲酯 | CAS号128781-80-6 (S)-2-((叔丁氧基羰基)... | CAS号1041-01-6 3,5-二碘-L-甲状腺素 | CAS号1027-28-7 N-乙酰基-3,5-二碘-L-酪氨酸 | CAS号1164-16-5 N-苄氧羰基-L-酪氨酸

3-碘-L-酪氨酸置于碘体系中,用 水 用作溶剂,化学反应 0.08H,反应生成3,5-二碘-L-酪氨酸
参考文献:Baldas,John; Colmanet,Silvano; Porter,Quentin N.,Australian Journal Of Chemistry,1981,Vol. 34,# 5,P. 1147-1151
标题:Baldas,John; Colmanet,Silvano; Porter,Quentin N.,Australian Journal Of Chemistry,1981,Vol. 34,# 5,P. 1147-1151

专利信息

专利号:US-4242256-A
优先权日:1977-03-15
标 题 :Synthesis of peptide analogues
发明人：SHARPE ROBERT; SZELKE MICHAEL
权利人:SHARPE ROBERT; SZELKE MICHAEL
摘要:Compounds being analogues of a dipeptide in which the nitrogen atom of the linking amide group of the dipeptide is replaced by trivalent group ##STR1## and in which, optionally, the carbonyl function of this linking group is replaced by the divalent group --CH 2 -- are of value in the synthesis of isosterically modified peptides.

专利号:US-10087221-B2
优先权日:2013-03-21
标题 :Synthesis of hydantoin containing peptide products
发明人：HENKEL BERND
权利人:SANOFI AVENTIS DEUTSCHLAND
摘要:The present invention relates to a method of synthesizing a peptide product comprising at least one hydantoin group. The peptide product may be used as a reference material for the quality control of pharmaceutical peptides, particularly for the quality control of exendin peptides. Further, the invention relates to hydantoin building blocks, a method for manufacturing such building blocks and their use for the synthesis of peptide products.

专利号:US-5446158-A
优先权日:1989-01-11
标题:Process for synthesis of FK-506 and tricarbonyl intermediates
发明人：JONES TODD K; MILLS SANDER G; ASKIN DAVID; REAMER ROBERT A; DESMOND RICHARD; TSCHAEN DAVID M; VOLANTE RALPH P; SHINKAI ICHIRO
权利人:MERCK & CO INC
摘要:A process is described for the total synthesis of the macrolide immunosuppressant, FK-506, and important tricarbonyl process intermediates thereof. The tricarbonyl intermediates can be produced by the mild oxidation of 2,3-dihydroxy carboxylate compounds containing olefin moieties.

专利号:US-2023212788-A1
优先权日:2020-03-26
标 题:New method for automated on-demand biomolecular array synthesis
发明人：ZHANG YIXIN; LIN WEILIN
权利人:UNIV DRESDEN TECH
摘要:The invention provides an amphiphilic coating for the direct and rapid synthesis of an array of peptides and small molecular compounds on a planar surface of a solid support, comprising a hydrophilic chemical structure and a lipophilic group, wherein said peptides and small molecular compounds differ from spot to spot from each other in the chemical structure, characterized in that said amphiphilic coating possesses low wettability to polar aprotic solvents used in the array synthesis; said amphiphilic coating possessing low wettability is designed that it can be converted to a coating possessing high wettability by hydrolysis of the lipophilic group; and said amphiphilic coating comprises an amino group for the reaction with an electrophilic reagent. The invention further provides a solid support comprising said amphiphilic coating and a method for method for the direct and rapid synthesis of an array of peptides and small molecular compounds on a planar surface of a solid support, wherein said planar surface of a solid support comprises said amphiphilic coating. Said method includes the enhancing of the wettability of a glass surface to organic solvents to realize automated on-demand biomolecular array synthesis comprising both, peptides and small molecular compounds. The amphiphilic surface can be switched to a hydrophilic surface, resulting in high density arrays suitable for protein- and cell-based screening.

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:WO-9101724-A1
优先权日:1989-07-27
标题 :Renal-selective prodrugs for the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as depa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitors compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-Y-glutamyl fusaric acid is preferred.